KR100834232B1 - 액체 투여형용 베타-시클로덱스트린을 사용하는 다수회투여 제형을 얻기 위한 항균 방부제 - Google Patents

액체 투여형용 베타-시클로덱스트린을 사용하는 다수회투여 제형을 얻기 위한 항균 방부제 Download PDF

Info

Publication number
KR100834232B1
KR100834232B1 KR1020067015283A KR20067015283A KR100834232B1 KR 100834232 B1 KR100834232 B1 KR 100834232B1 KR 1020067015283 A KR1020067015283 A KR 1020067015283A KR 20067015283 A KR20067015283 A KR 20067015283A KR 100834232 B1 KR100834232 B1 KR 100834232B1
Authority
KR
South Korea
Prior art keywords
formula
cyclodextrin
cresol
meta
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020067015283A
Other languages
English (en)
Korean (ko)
Other versions
KR20060128973A (ko
Inventor
로저 크리스토퍼 아다미
프레데릭 데이비드
줄리아 앤 우드
Original Assignee
화이자 프로덕츠 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34910697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100834232(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 화이자 프로덕츠 인크. filed Critical 화이자 프로덕츠 인크.
Publication of KR20060128973A publication Critical patent/KR20060128973A/ko
Application granted granted Critical
Publication of KR100834232B1 publication Critical patent/KR100834232B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
KR1020067015283A 2004-01-30 2005-01-17 액체 투여형용 베타-시클로덱스트린을 사용하는 다수회투여 제형을 얻기 위한 항균 방부제 Expired - Lifetime KR100834232B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54089704P 2004-01-30 2004-01-30
US60/540,897 2004-01-30

Publications (2)

Publication Number Publication Date
KR20060128973A KR20060128973A (ko) 2006-12-14
KR100834232B1 true KR100834232B1 (ko) 2008-05-30

Family

ID=34910697

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067015283A Expired - Lifetime KR100834232B1 (ko) 2004-01-30 2005-01-17 액체 투여형용 베타-시클로덱스트린을 사용하는 다수회투여 제형을 얻기 위한 항균 방부제

Country Status (25)

Country Link
US (1) US8183230B2 (enExample)
EP (1) EP1713504B1 (enExample)
JP (1) JP5021318B2 (enExample)
KR (1) KR100834232B1 (enExample)
CN (1) CN101090735A (enExample)
AR (2) AR047469A1 (enExample)
AU (1) AU2005216709B2 (enExample)
BR (1) BRPI0506496B8 (enExample)
CA (1) CA2554346C (enExample)
CO (1) CO5700794A2 (enExample)
CY (1) CY1119188T1 (enExample)
DK (1) DK1713504T3 (enExample)
ES (1) ES2638113T3 (enExample)
HU (1) HUE034099T2 (enExample)
IL (1) IL176676A0 (enExample)
LT (1) LT1713504T (enExample)
NO (1) NO20063858L (enExample)
NZ (1) NZ548236A (enExample)
PL (1) PL1713504T3 (enExample)
PT (1) PT1713504T (enExample)
RU (1) RU2332997C2 (enExample)
SI (1) SI1713504T1 (enExample)
TW (1) TW200524632A (enExample)
WO (1) WO2005082416A2 (enExample)
ZA (1) ZA200605148B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013273764B2 (en) * 2011-11-29 2016-05-05 Zoetis Services Llc Pharmaceutical compositions
SG11201401597TA (en) * 2011-11-29 2014-05-29 Jurox Pty Ltd Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
DK3021832T3 (da) * 2013-07-19 2021-05-25 Boehringer Ingelheim Vetmedica Gmbh Konserverede etherificerede cyclodextrinderivater indeholdende flydende vandig farmaceutisk sammensætning
ES2593210T3 (es) 2013-12-04 2016-12-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmacéuticas mejoradas de pimobendán
NL2015865B1 (en) 2015-11-27 2017-06-13 Le Vet B V Maropitant Formulation.
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
KR20250069704A (ko) 2017-06-30 2025-05-19 체이스 테라퓨틱스 코포레이션 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
JP7455852B2 (ja) * 2019-02-15 2024-03-26 ソール インターナショナル ディベロップメント エルティーディー． 注射可能なフェノール製剤およびその使用の方法
EP3725298A1 (en) 2019-04-16 2020-10-21 Faes Farma, S.A. Stable and preserved pharmaceutical compositions of bilastine
CN112370451A (zh) * 2020-12-08 2021-02-19 河北科技大学 一种枸橼酸马罗匹坦包合物、注射液及制备方法
AT527172A1 (de) 2023-04-25 2024-11-15 Vetviva Richter Gmbh Maropitantformulierung

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6419737A (en) * 1987-07-15 1989-01-23 Hitachi Ltd Multilayer interconnection tape carrier
JPH039848A (ja) * 1989-06-06 1991-01-17 Canon Inc 液体噴射記録装置

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5910510A (ja) * 1982-07-08 1984-01-20 Nippon Zenyaku Kogyo Kk 低刺激性チアムリン注射剤
JPS59152320A (ja) * 1983-02-17 1984-08-31 Takeda Chem Ind Ltd 水性製剤
RU2103269C1 (ru) 1991-05-31 1998-01-27 Пфайзер Инк. Производные хинуклидина или их фармацевтически приемлемые соли и фармацевтическая композиция
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
AU676489B2 (en) 1992-11-12 1997-03-13 Pfizer Inc. Quinuclidine derivative as substance P antagonist
US5393762A (en) 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP1109581A1 (en) * 1998-09-02 2001-06-27 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US6255320B1 (en) 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
AU5975700A (en) * 1999-07-02 2001-01-22 Janssen Pharmaceutica N.V. Nasal formulation of an antifungal
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
WO2002074200A1 (en) * 2001-03-20 2002-09-26 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
CN1529600A (zh) * 2001-07-20 2004-09-15 �Ʒ� Nk-1受体拮抗剂在改变狗、猫和马的不需要行为中的用途
MXPA04008173A (es) 2002-02-22 2004-11-26 Pharmacia Corp Formulaciones de farmaco antibiotico oftalmico que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio.
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
DE10228049A1 (de) 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
MXPA06007964A (es) 2004-01-30 2007-01-26 Pfizer Prod Inc Antagonistas del receptor nk-1 para mejorar la recuperacion de anestesia.
WO2005082419A1 (en) 2004-01-30 2005-09-09 Pfizer Products Inc. Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration
PT1713801E (pt) 2004-02-02 2008-02-11 Pfizer Prod Inc Processo para a preparação de 1-(2s,3s)-2-benzidril-n-(5- -terc-butil-2-metoxibenzil)-quinuclidina-3-amina

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6419737A (en) * 1987-07-15 1989-01-23 Hitachi Ltd Multilayer interconnection tape carrier
JPH039848A (ja) * 1989-06-06 1991-01-17 Canon Inc 液体噴射記録装置

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
국제공개특허공보 제03/009848호*
유럽공개특허공보 제119737호*

Also Published As

Publication number Publication date
CA2554346C (en) 2009-11-17
EP1713504A2 (en) 2006-10-25
NZ548236A (en) 2010-02-26
KR20060128973A (ko) 2006-12-14
RU2006127422A (ru) 2008-03-10
RU2332997C2 (ru) 2008-09-10
JP2007519703A (ja) 2007-07-19
BRPI0506496B1 (pt) 2018-10-09
LT1713504T (lt) 2017-09-11
EP1713504B1 (en) 2017-06-07
JP5021318B2 (ja) 2012-09-05
DK1713504T3 (en) 2017-08-07
BRPI0506496A (pt) 2007-02-13
ZA200605148B (en) 2007-10-31
US8183230B2 (en) 2012-05-22
ES2638113T3 (es) 2017-10-18
IL176676A0 (en) 2006-10-31
AU2005216709B2 (en) 2008-02-07
CO5700794A2 (es) 2006-11-30
AR047469A1 (es) 2006-01-18
BRPI0506496A8 (pt) 2017-11-14
SI1713504T1 (sl) 2017-10-30
US20070155697A1 (en) 2007-07-05
BRPI0506496B8 (pt) 2022-09-20
WO2005082416A3 (en) 2006-07-27
PL1713504T3 (pl) 2017-12-29
CA2554346A1 (en) 2005-09-09
PT1713504T (pt) 2017-08-29
WO2005082416A2 (en) 2005-09-09
AR109357A2 (es) 2018-11-21
CN101090735A (zh) 2007-12-19
CY1119188T1 (el) 2018-02-14
TW200524632A (en) 2005-08-01
AU2005216709A1 (en) 2005-09-09
HUE034099T2 (en) 2018-01-29
NO20063858L (no) 2006-10-19

Similar Documents

Publication Publication Date Title
US12357696B2 (en) Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
US20240307368A1 (en) Antimicrobial compositions
EP2785352B1 (en) Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone
KR100834232B1 (ko) 액체 투여형용 베타-시클로덱스트린을 사용하는 다수회투여 제형을 얻기 위한 항균 방부제
US20070129328A1 (en) Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration
MXPA06008032A (en) Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms
HK1115057A (en) Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms
HK1198325B (en) Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20130429

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20140430

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20160330

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20170330

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20180329

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

FPAY Annual fee payment

Payment date: 20190327

Year of fee payment: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 14

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 15

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 16

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 17

PC1801 Expiration of term

St.27 status event code: N-4-6-H10-H14-oth-PC1801

Not in force date: 20250118

Ip right cessation event data comment text: Termination Category : EXPIRATION_OF_DURATION